Menu Search
Equities

COSCIENS Biopharma Inc

ET8:BER

COSCIENS Biopharma Inc

Actions
  • Price (EUR)4.84
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change-49.69%
  • Beta--
Data delayed at least 15 minutes, as of Aug 08 2024 07:01 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year COSCIENS Biopharma Inc had revenues fall -20.25% from 5.64m to 4.50m, though the company grew net income from a loss of 22.73m to a smaller loss of 16.55m.
Gross margin39.42%
Net profit margin-278.95%
Operating margin-365.76%
Return on assets-26.11%
Return on equity-45.58%
Return on investment-30.53%
More ▼

Cash flow in USDView more

In 2023, cash reserves at COSCIENS Biopharma Inc fell by 16.60m. However, Cash Flow from Investing totalled 528.00k, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 17.12m for operations while cash used for financing totalled 151.00k.
Cash flow per share-9.44
Price/Cash flow per share--
Book value per share11.62
Tangible book value per share10.15
More ▼

Balance sheet in USDView more

COSCIENS Biopharma Inc appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 1.66% of the market capitalization can be attributed to its 34.02m and debt could be paid in full if management chose.
Current ratio3.36
Quick ratio3.05
Total debt/total equity0.0643
Total debt/total capital0.0604
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.